Novo Nordisk shares rise after Wegovy obesity pill launch
A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, US, on Thursday, Jan. 15, 2026....
HEALTH & FITNESS
Novo Nordisk CEO talks GLP-1 pill at JPMorgan conference
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to...
OpenAI acquires health-care technology startup Torch
OpenAI has acquired the health-care technology startup Torch, the company announced on Monday. OpenAI purchased Torch for roughly $60 million,...
Thanks for your support, here’s how to connect with us
When Becky Quick announced the CNBC Cures initiative, our effort to raise awareness for rare diseases and improve the lives of the...
2026 is the year of obesity pills from Novo Nordisk, Eli Lilly
The booming GLP-1 space was built on weekly injections. In 2026, new obesity pills will push the market into its...
What to expect from pharma at the JPM conference
Heidi Overton, Novo Nordisk CEO Maziar Mike Doustdar, Eli Lilly CEO David A. Ricks, and U.S. Secretary of Commerce Howard...
Abivax’s stock surged to become a prime biotech takeover target
Europe's best-performing blue-chip stock in 2025 is widely expected to be bought by a larger peer, in a deal analysts...
Patient advocates urge U.S. court to halt AFP prescription operations
In a photo illustration, prescription drugs are seen next to a pill bottle on July 23, 2024 in New York.Spencer...
CNBC launches initiative to help 30 million Americans rare diseases
Thirty million. It's a big number. Maybe not in the context of business news, where we usually talk about company...
OpenAI launches ChatGPT Health to connect user medical records
OpenAI CEO Sam Altman attends an event to pitch AI for businesses in Tokyo, Feb. 3, 2025.Kim Kyung-hoon | ReutersOpenAI...
First GLP-1 pill for obesity from Novo Nordisk launches in the U.S.
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of...
These stocks will benefit from new habits
The ripple is about to become a wave. Right now, there are numerous barriers for people who are considering treating...
Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale
Jim Cramer says don't sweat Novo Nordisk's head start over Club holding Eli Lilly in the obesity pill market. Eli...
Wegovy-maker Novo Nordisk shares surge after GLP-1 pill approval
Shares in Novo Nordisk surged 6% Tuesday, after the Wegovy maker secured approval of its GLP-1 pill — a world...
FDA approves first GLP-1 pill for obesity from Novo Nordisk
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of...
How donors, access and polls led Trump to reclassify marijuana
President Donald Trump's move Thursday to sign an executive order easing federal restrictions on marijuana — and clearing the way...
Wall Street deals 2025 under Trump: Tariffs, uncertainty slow M&A
The Wall Street Bull statue covered in snow on Nov. 15, 2018.Erik Mcgregor | Lightrocket | Getty ImagesWall Street expected...
UnitedHealth Group releases results of independent audit
UnitedHealthcare sign is displayed at its office building in Minnetonka, Minnesota, U.S., Dec. 11, 2025. Tim Evans | ReutersUnitedHealth Group...
Trump reclassifies cannabis to Schedule III, easing weed restrictions
U.S. President Donald Trump sits in the Oval Office to sign executive orders, at the White House in Washington, D.C.,...
Eli Lilly obesity pill maintains weight loss after Wegovy, Zepbound
Eli Lilly on Thursday said its closely watched obesity pill helped patients maintain the majority of their weight loss after...
